Evidence map›Paper›PMID 36075194›Full record

ArticleDigestion2022

Analysis of Barrett's Esophagus and Its Risk Factors: A Cross-Sectional Study of 10,122 Subjects at a Japanese Health Examination Center.

Dai Kubota, Yu Takahashi, Nobutake Yamamichi, Maki Matsui, Takeshi Shimamoto, Chihiro Minatsuki, Hideki Nakagawa, Satoru Mizutani, Yosuke Tsuji, Yoshiki Sakaguchi and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Development of a prediction score for Barrett's esophagus in Japanese health checkup settings.Esophagus : official journal of the Japan Esophageal Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Dai KubotaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, kubota-tuk@umin.ac.jp.
Yu TakahashiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nobutake YamamichiCenter for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Maki MatsuiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takeshi ShimamotoKameda Medical Center Makuhari, Chiba, Japan.
Chihiro MinatsukiInfection Control and Prevention Service, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hideki NakagawaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoru MizutaniDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yosuke TsujiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshiki SakaguchiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Naoki TamuraDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Seiichi YakabiCenter for International Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daisuke OhkiInfection Control and Prevention Service, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroya MizutaniDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Keiko NiimiCenter for Epidemiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Ryoichi WadaKameda Medical Center Makuhari, Chiba, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPKameda Medical Center · JPUniversity of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHelicobacter pylori eradication is expected to significantly change the prevalence of Barrett's esophagus (BE). However, few reports on this relationship exist. We analyzed the risk factors of BE using the current consensus on length of BE considering H. pylori infection status.

methodsWe analyzed 10,122 individuals (5,962 men; mean age = 52.9 ± 9.9 years) who had undergone esophagogastroduodenoscopy as part of a medical checkup. Correlations among factors including H. pylori infectious status, endoscopic findings, and BE ≥1 cm were analyzed.

resultsPrevalence of BE, long-segment BE, and esophageal adenocarcinoma was 22.5%, 0.014%, and 0%, respectively. Logistic regression analysis showed that the risk factors for BE were hiatal hernia (odds ratio [OR]: 2.89 [2.59-3.24]), female sex (OR: 0.52 [0.46-0.59]), social drinking (OR:0.77 [0.68-0.87]), H. pylori eradication therapy (OR: 1.34 [1.19-1.51]), proton pump inhibitor (PPI) use (OR: 1.52 [1.18-1.96]), bile reflux (OR: 1.18 [1.04-1.33]), age ≥50 years (OR: 1.13 [1.02-1.26]), and nonsteroidal anti-inflammatory drug (NSAID) use (OR: 1.29 [1.02-1.62]). Although reflux esophagitis (RE) was more common in H. pylori-negative patients (17.2%) than in those after H. pylori eradication therapy (11.8%, p < 0.00001), the latter was correlated with BE, disputing RE as a strong risk factor for BE. Therefore, we conducted a subgroup analysis; most of the risk factors except for PPI use (p = 0.75), H2-receptor antagonist use (p = 0.078), and atrophic gastritis absence (p = 0.72) were positively correlated with BE after H. pylori eradication therapy compared with H. pylori-negative status.

conclusionsH. pylori eradication, bile reflux, PPI use, and NSAID use were risk factors for BE along with hiatal hernia, male sex, and older age.

Indexed as

Barrett EsophagusBile RefluxEsophagitis, PepticHelicobacter InfectionsHelicobacter pyloriHernia, HiatalAdultAnti-Inflammatory Agents, Non-SteroidalCross-Sectional StudiesFemaleHumansJapanMaleMiddle AgedProton Pump InhibitorsRisk FactorsAnti-Inflammatory Agents, Non-SteroidalProton Pump InhibitorsBarrett’s esophagusBile refluxHelicobacter pyloriHelicobacter pylori eradication

Identifiers

PMID36075194
PMCPMC9808710
OpenAlexW4294970485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.